These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 9846887)
1. Advanced glycated albumin impairs protein degradation in the kidney proximal tubules cell line LLC-PK1. Sebeková K; Schinzel R; Ling H; Simm A; Xiang G; Gekle M; Münch G; Vamvakas S; Heidland A Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1051-60. PubMed ID: 9846887 [TBL] [Abstract][Full Text] [Related]
2. Advanced glycation end products impair protein turnover in LLC-PK1: amelioration by trypsin. Xiang G; Schinzel R; Simm A; Sebekova K; Heidland A Kidney Int Suppl; 2001 Feb; 78():S53-7. PubMed ID: 11168983 [TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner. Gallicchio MA; McRobert EA; Tikoo A; Cooper ME; Bach LA J Am Soc Nephrol; 2006 Feb; 17(2):414-21. PubMed ID: 16371434 [TBL] [Abstract][Full Text] [Related]
4. In vitro-prepared advanced glycation end-products and the modulating potential of their low-molecular weight degradation products in IRPTC-A rat proximal-tubular derived kidney epithelial cell line. Deuther-Conrad W; Franke S; Henle T; Sommer M; Stein G Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL187-96. PubMed ID: 11936867 [TBL] [Abstract][Full Text] [Related]
5. Effects of advanced glycosylation end products and rosiglitazone on the expression and secretion of galectin-3 in human renal mesangial cells. Sun ZL; Ma CJ; Jin H; Yuan Y; Liu NF Chin Med J (Engl); 2009 May; 122(9):1067-71. PubMed ID: 19493442 [TBL] [Abstract][Full Text] [Related]
6. Advanced glycation end-products induce cell cycle arrest and hypertrophy in podocytes. Rüster C; Bondeva T; Franke S; Förster M; Wolf G Nephrol Dial Transplant; 2008 Jul; 23(7):2179-91. PubMed ID: 18344241 [TBL] [Abstract][Full Text] [Related]
7. Impact of high glucose and AGEs on cultured kidney-derived cells. Effects on cell viability, lysosomal enzymes and effectors of cell signaling pathways. Peres GB; Schor N; Michelacci YM Biochimie; 2017 Apr; 135():137-148. PubMed ID: 28229902 [TBL] [Abstract][Full Text] [Related]
8. Angiotensin-II-induced cell hypertrophy: potential role of impaired proteolytic activity in cultured LLC-PK1 cells. Ling H; Vamvakas S; Schaefer L; Schnittler HJ; Schaefer RM; Heidland A Nephrol Dial Transplant; 1995; 10(8):1305-12. PubMed ID: 8538919 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of GSPE on RAGE expression induced by advanced glycation end products in endothelial cells. Zhang FL; Gao HQ; Shen L J Cardiovasc Pharmacol; 2007 Oct; 50(4):434-40. PubMed ID: 18049312 [TBL] [Abstract][Full Text] [Related]
10. Effects of advanced glycation end product modification on proximal tubule epithelial cell processing of albumin. Ozdemir AM; Hopfer U; Rosca MV; Fan XJ; Monnier VM; Weiss MF Am J Nephrol; 2008; 28(1):14-24. PubMed ID: 17890854 [TBL] [Abstract][Full Text] [Related]
11. Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1. Xiang G; Schinzel R; Simm A; Münch G; Sebekova K; Kasper M; Niwa T; Schmitz C; Heidland A Nephrol Dial Transplant; 2001 Aug; 16(8):1562-9. PubMed ID: 11477156 [TBL] [Abstract][Full Text] [Related]
12. Expression of platelet-endothelial cell adhesion molecule-1 in human umbilical vein endothelial cells by exposure to advanced glycosylation end products and inflammatory mediators. Meng D; Liu N Chin Med J (Engl); 2003 Sep; 116(9):1336-40. PubMed ID: 14527361 [TBL] [Abstract][Full Text] [Related]
13. Uptake of advanced glycation end products by proximal tubule epithelial cells via macropinocytosis. Gallicchio MA; Bach LA Biochim Biophys Acta; 2013 Dec; 1833(12):2922-2932. PubMed ID: 23747564 [TBL] [Abstract][Full Text] [Related]
14. Advanced glycosylation end products stimulate collagen mRNA synthesis in mesangial cells mediated by protein kinase C and transforming growth factor-beta. Kim YS; Kim BC; Song CY; Hong HK; Moon KC; Lee HS J Lab Clin Med; 2001 Jul; 138(1):59-68. PubMed ID: 11433229 [TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Yamagishi S; Inagaki Y; Okamoto T; Amano S; Koga K; Takeuchi M Kidney Int; 2003 Feb; 63(2):464-73. PubMed ID: 12631112 [TBL] [Abstract][Full Text] [Related]
16. Cathepsins D and L reduce the toxicity of advanced glycation end products. Grimm S; Horlacher M; Catalgol B; Hoehn A; Reinheckel T; Grune T Free Radic Biol Med; 2012 Mar; 52(6):1011-23. PubMed ID: 22245096 [TBL] [Abstract][Full Text] [Related]
17. Impairment of human keratinocyte mobility and proliferation by advanced glycation end products-modified BSA. Zhu P; Yang C; Chen LH; Ren M; Lao GJ; Yan L Arch Dermatol Res; 2011 Jul; 303(5):339-50. PubMed ID: 21132435 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of Na superset+/H superset+ exchange decreases albumin-induced NF-kappaB activation in renal proximal tubular cell lines (OK and LLC-PK1 cells). Drumm K; Gassner B; Silbernagl S; Gekle M Eur J Med Res; 2001 Oct; 6(10):422-32. PubMed ID: 11698229 [TBL] [Abstract][Full Text] [Related]
19. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats. Chen SX; Song T; Zhou SH; Liu YH; Wu SJ; Liu LY Eur J Pharmacol; 2008 Apr; 584(2-3):368-75. PubMed ID: 18334254 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of human endothelial cell nitric oxide synthesis by advanced glycation end-products but not glucose: relevance to diabetes. Xu B; Ji Y; Yao K; Cao YX; Ferro A Clin Sci (Lond); 2005 Nov; 109(5):439-46. PubMed ID: 16022682 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]